Athersys Finishes Enrollment of Phase 2 Study of MultiStem(R) Cell Therapy for Ischemic Stroke Top-Line Data Readout Expected Around the End of the First Quarter, 2015
Top-Line Data Readout Expected Around the End of the First Quarter, 2015
CLEVELAND, Dec. 29, 2014 (GLOBE NEWSWIRE) — Athersys, Inc. (Nasdaq:ATHX) today announced that it has concluded patient enrollment of its Phase 2 clinical study involving administration of Athersys’ MultiStem® cell therapy to ischemic stroke patients. The study is a randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating the safety and efficacy of MultiStem therapy in subjects suffering moderate to moderate-severe ischemic strokes. Athersys expects initial results from the study to be disclosed around the end of the first quarter of 2015.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.